Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 683 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Long-Term Responders with No Evidence of Disease Have Better Survival to... May 16, 2022 Addition of an EGFR Antibody to Fluorouracil/Folinic Acid Maintenance Therapy in... September 22, 2021 Time to meet our new chief scientist – Professor KJ Patel October 12, 2022 FDA Approves Omidubicel to Reduce Time to Neutrophil Recovery and Infection... April 25, 2023 Load more HOT NEWS FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma Clinical Benefit and Safety of Encorafenib Plus Binimetinib in Treatment-Naïve and... Teen Helps Mom With Cancer Shave Her Head, Then Turns To... Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for...
